BPMC:NSD-Blueprint Medicines Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 101.36

Change

+1.50 (+1.50)%

Market Cap

USD 5.57B

Volume

0.33M

Average Target Price

USD 114.20 (+12.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.05 (-0.44%)

USD62.06B 23.39 18.26
REGN Regeneron Pharmaceuticals, Inc

+2.30 (+0.43%)

USD57.14B 19.62 14.64
MRNA Moderna, Inc

-1.96 (-1.47%)

USD52.62B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.87 (+1.18%)

USD34.53B 36.64 33.83
SGEN Seagen Inc

-3.03 (-1.63%)

USD33.25B 70.16 70.76
BGNE BeiGene, Ltd

+17.51 (+4.90%)

USD32.53B N/A N/A
RPRX Royalty Pharma plc

+0.74 (+1.47%)

USD31.52B 22.60 11.90
GMAB Genmab A/S

-0.01 (-0.02%)

USD28.49B 26.59 3.08
BNTX BioNTech SE

+3.01 (+2.85%)

USD25.39B -99,999.99 N/A
INCY Incyte Corporation

+3.99 (+4.25%)

USD20.56B 47.64 35.20

ETFs Containing BPMC

Symbol Name Weight Mer Price(Change) Market Cap
RYJ Invesco Raymond James SB-.. 0.00 % 0.82 %

+0.15 (+0.28%)

USD0.12B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.40 (+0.72%)

USD0.26B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.62% 4% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.62% 4% F 4% F
Trailing 12 Months  
Capital Gain 54.56% 63% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.56% 63% D 74% C
Trailing 5 Years  
Capital Gain 473.63% 89% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 473.63% 89% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 49.37% 79% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.37% 79% C+ 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 63.73% 41% F 19% F
Risk Adjusted Return 77.46% 94% A 86% B
Market Capitalization 5.57B 92% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.16 38% F 58% F
Price/Book Ratio 4.26 56% F 37% F
Price / Cash Flow Ratio -20.02 77% C+ 84% B
EV/EBITDA 14.96 25% F 55% F
Management Effectiveness  
Return on Equity 36.29% 99% A+ 97% A+
Return on Invested Capital -96.87% 27% F 10% F
Return on Assets 17.71% 99% A+ 99% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.78 36% F 28% F
Short Percent 5.73% 56% F 36% F
Beta 0.91 77% C+ 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector